Atlas Trials

Capecitabine Versus Vinorelbine in High Risk Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy

Clinical trial NCT03703427 · UNKNOWN

Trial details

NCT number
NCT03703427
Sponsor
Zhiyong Yu
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Pathologic Residual Cancer Cells
Start date
2018-11-01
Primary completion
2023-11-01
Enrollment
200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.